Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetRevenue - OtherRevenue - Rental
Ratios

Maxcyte (MXCT) Cost of Revenue (2020 - 2025)

Maxcyte (MXCT) has disclosed Cost of Revenue for 6 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 36.59% to $3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.9 million, a 2.19% increase, with the full-year FY2024 number at $26.7 million, down 1.16% from a year prior.
  • Cost of Revenue was $3.9 million for Q3 2025 at Maxcyte, down from $5.8 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $11.7 million in Q2 2023 to a low of $693100.0 in Q1 2021.
  • A 5-year average of $4.1 million and a median of $3.9 million in 2025 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: plummeted 61.54% in 2022, then surged 947.13% in 2023.
  • Maxcyte's Cost of Revenue stood at $1.2 million in 2021, then increased by 26.12% to $1.5 million in 2022, then skyrocketed by 365.49% to $7.2 million in 2023, then fell by 10.06% to $6.5 million in 2024, then crashed by 39.19% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cost of Revenue are $3.9 million (Q3 2025), $5.8 million (Q2 2025), and $5.7 million (Q1 2025).